comprehensive -WSS

comprehensive

author：entertainment 2025-09-30 18:53:53 - browse：3

Doctor holding a clipboard. -- health coverage from STAT — Adobe

The momentum around weight loss drugs is about to get even bigger in the wake of Novo Nordisk’s announcement that its semaglutide drug Wegovy cut the risk of cardiovascular disease by 20% in its large SELECT trial.

The full results of the study, funded by Novo, will be presented at the American Heart Association meeting in November. Doctors and researchers say they expect the findings to have a big impact on how clinicians approach the treatment of both obesity and cardiovascular disease, as well as increase the likelihood that prescriptions for obesity drugs will be covered by insurance.

But experts who spoke with STAT also cautioned that the long-term safety and efficacy of Wegovy and other weight loss drugs remain unknown. The SELECT study has yet to be peer-reviewed, and not enough information is yet available to make independent assessments of the results.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED Log In

Previous article： Medical leaders decry Supreme Court decision on affirmative action
Next article： WHO recommends dropping component of many flu vaccines

hotspot

WSS

Would Medicare drug price negotiations stall in a shutdown?

DeSantis can now import cheaper drugs. But will Biden get credit?

Cigna to pay $172 million to settle Medicare Advantage fraud probe

Senator probes 340B programs at Cleveland Clinic, Bon Secours

Biogen shutters digital health group, ends Apple study, in cost cutting move

Heart disease and mental health: A look at cardiac psychology

explore

comprehensive

knowledge

How to save PrEP access — and even expand it

HHS names first

Indiana Supreme Court upholds abortion ban, says state constitution gives only limited protections

After a drawn out lobbying fight, ARPA

Medicare details structure of new drug price negotiation program

HHS names first

In Memoriam: Notable people who died in 2023

Risky weight loss products often used by teens globally, per study

Biden outlines 'new path' to provide student loan relief after Supreme Court rejection

Address the ethical violations that led to 'Three Identical Strangers'

hotspot

As JPM 2024 winds down, some health tech firms project optimism

Why do women spend more than men on medical expenses?

How one patient went off dialysis — and others can too

FDA advisers vote against ALS treatment from BrainStorm

Listen: Who gets the credit for GLP

Readout LOUD podcast: 2023 in review, and a look at biotech in 2024

focus

hotspot

explore

entertainment